Bristol-Myers Squibb (BMS) has announced that construction is underway for a new cell-therapy manufacturing facility at its biomanufacturing site in Devens, Massachusetts.

The new cell-therapy facility will be located on BMS’s current 89-acre Devens campus that supports process development, clinical manufacturing and commercial manufacturing for biologics medicines. The new 244,000-square-foot facility, which will have clinical and commercial-scale capacity, will add to the company’s cell-therapy manufacturing network, which includes facilities in Bothell, Washington, Summit, New Jersey, and Warren, New Jersey as well as external manufacturing facilities in the US, Europe, and Japan

The company plans to hire several hundred employees over the next few years (as reported on February 23, 2021) to support the new operations.

BMS also operates two R&D facilities in Cambridge, Massachusetts and will be bringing those two sites together into a new building in 2023.

Source: Bristol-Myers Squibb